Patients were more likely to report more relapses of multiple sclerosis than physicians.
The voice and preferences of the patient have become increasingly important in healthcare decisions as well as for endpoints in studies for a myriad of conditions, including multiple sclerosis (MS). However, more data comparing patient-reported relapses with physician-documented relapses is needed.
Seeking this out, researchers compared 2 years’ worth of data from 2 prospective, noninterventional, multicenter studies in Germany, finding that patients and physicians data on the occurrence of MS relapse was generally in line, although patients on average reported more relapses.
The 2 studies were comprised of 1921 patients with relapsing remitting MS being treated with interferon-beta preparations, glatiramer acetate, or fingolimod. Every 3 months, both patients and their neurologists documented the presence and absence of relapses for an average of 2 years per patient.
Analyzing these assessments, the researchers of the current study found an overwhelming agreement between the 2 groups, with an absolute agreement of 96.7%. The researchers adjusted for chance and interrater reliability, determining a good agreement between patients and their neurologists (κ = 0.78, 95% CI, 0.76–0.80).
Generally, patients were more likely to report more relapses, with an average number of 0.55 relapses during follow-up compared with an average number of 0.44 physician-reported relapses. Overreporting of relapses was more common among patients who were younger and had greater disability levels, as well as lower health-related quality of life or treatment satisfaction.
The overreporting by patients could be explained by pseudo-relapses, which are characterized by symptoms representing physiological processes other than true relapses, according to the researchers. While differential diagnoses are considered by the neurologist in clinical practice, patients might interpret pseudo-relapses, symptom fluctuation, or single paroxysmal symptoms as true relapses.
However, despite the slight difference in relapse reporting, both the patient- and neurologist-reported relapses were in concurrence with the ranges observed in previous studies, noted the researchers.
“Not only do definitions of what constitutes a relapse differ, but also fixed protocol definitions can remain susceptible to varying interpretations by physicians, especially at different levels of clinical experience,” noted the researchers, reflecting on the difference in reporting. “To date, there is no ‘gold standard’ for MS relapse that ensures a fully objective relapse assessment. Whether in clinical trials or in clinical practice, relapses may be undetected, and even experienced MS clinicians may sometimes have difficulty in identifying relapses.”
Reference
Schriefer D, Haase R, Ettle B, Ziemssen T. Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study. Eur J Neurol. Published online July 9, 2020. doi: 10.1111/ene.14432.
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More